GlassScriptPhysician profile
Mee Wah Loo
NPI 1861738866
$4,159.30
in general payments reported to CMS, 2019-2025
17 companies · $1,514 in 2025
The $1,514 reported for 2025 was more than what 90% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $20.45 · 2023: $650 · 2024: $1,974 · 2025: $1,514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,120 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,119.59 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,056.95 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $568.72 | 2023-2025 | Nuplazid |
| Lundbeck LLC | $475.43 | 2023-2025 | Rexulti, Vyepti |
| Amneal Pharmaceuticals LLC | $399.97 | 2024-2025 | Crexont, Ongentys |
| Axsome Therapeutics, INC. | $389.49 | 2024-2025 | Symbravo, Auvelity |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $245.41 | 2025 | |
| Ucb, INC. | $225.88 | 2023-2025 | Briviact |
| Otsuka America Pharmaceutical, INC. | $208.64 | 2023-2025 | Rexulti, Nuedexta |
| Idorsia Pharmaceuticals US INC | $169.56 | 2023 | Quviviq |
| Pfizer INC. | $151.56 | 2023-2025 | |
| Lilly USA, LLC | $104.15 | 2024 | Emgality |
| Ipsen Biopharmaceuticals, INC | $42.84 | 2023-2024 | Dysport |
| Argenx US, INC. | $40.38 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Astrazeneca Pharmaceuticals LP | $20.86 | 2023 | Wainua |
| Biohaven Pharmaceutical Holding Company LTD. | $20.45 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $19.75 | 2023 | Ingrezza, Ongentys |
| Mdd US Operations, LLC | $19.26 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mee Wah Loo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.